For latest News and updates
Sep 17, 2020
In women with metastatic breast cancer, programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors are given as the primary line of monotherapy. However, in patients with hormone receptor-positive...
Read MoreAug 25, 2020
Neoadjuvant chemotherapy is routinely assigned to women with early-stage breast cancer, but approximately 25% of them experience a recurrence within 5 years. Combining pembrolizumab, a humanized antibody, with neoadjuvant...
Read MoreAug 17, 2020
Several studies have been conducted to investigate the association between breastfeeding and ovarian cancer; some show a positive association, and some show no association at all. This study aims to determine the exact...
Read MoreAug 11, 2020
Transgender people undergo prolonged hormone treatment, which may be associated with an increased risk of breast cancer. This study aims to evaluate the incidence of breast cancer in trans men and women who received...
Read MoreMay 20, 2020
Three days packed with presentations The American Society of Clinical Oncology is the leading oncology research meeting worldwide, but just like other medical conferences, ASCO 2020 was forced to make many changes to deliver on...
Read MoreMay 1, 2020
Although research has linked pre-existing intratumoral immune response—characterized by presence of tumor-infiltrating lymphocytes or cytotoxic effector T cells—with improve prognosis in early triple-negative breast cancer...
Read MoreMay 1, 2020
Despite research suggesting that mutation in ESR1 is an acquired mechanism of resistance to endocrine therapy (ET), the impact of this mutation on therapy response in primary breast cancer remains unclear. To better understand...
Read MoreApr 24, 2020
New Tx available to patients who have tried two prior treatments WASHINGTON — Sacituzumab govitecan-hziy (Trodelvy) is now FDA-approved to treat adults with metastatic triple-negative breast cancer.The drug — which...
Read MoreApr 23, 2020
More than 33% of women treated with dual HER2 blockade plus docetaxel were still alive 8 years after Dx Previously reported improvements in overall survival (OS) with dual HER2 receptor blockade plus docetaxel in HER2-positive...
Read More